Q-omics provides the consensus-scored DMRTA2 profile across patient tissues and cancer cell-line models. DMRTA2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DMRTA2 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, DMRTA2 RNA expression shows 9,434 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, LUAD, and ESCA as cancer lineages where DMRTA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DMRTA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DMRTA2 survival associations across molecular data types. DMRTA2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DMRTA2 RNA expression–survival associations across cancer types. High DMRTA2 expression shows unfavorable associations in KIRC, ACC, LGG, DLBC and UVM, but favorable associations in LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DMRTA2 RNA expression.
This table summarizes DMRTA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DMRTA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DMRTA2 shows higher tumor expression in LUAD, HNSC, BLCA, UCEC, LUSC and COAD. The LUAD box plot shows higher DMRTA2 RNA expression in tumor versus normal tissue (log2 FC = +1.390, t-test p < 0.001).
This table shows molecular features associated with DMRTA2 in patient tissues and cancer cell lines. In patient samples, DMRTA2 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, DMRTA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
